169 related articles for article (PubMed ID: 36522365)
1. Trametinib improves Treg selectivity of anti-CCR4 antibody by regulating CCR4 expression in CTLs in oral squamous cell carcinoma.
Ono S; Suzuki S; Kondo Y; Okubo I; Goto M; Ogawa T; Kato H; Ito H; Takahara T; Satou A; Tsuzuki T; Yoshikawa K; Nagao T; Ueda R
Sci Rep; 2022 Dec; 12(1):21678. PubMed ID: 36522365
[TBL] [Abstract][Full Text] [Related]
2. Improving function of cytotoxic T-lymphocytes by transforming growth factor-β inhibitor in oral squamous cell carcinoma.
Kondo Y; Suzuki S; Takahara T; Ono S; Goto M; Miyabe S; Sugita Y; Ogawa T; Ito H; Satou A; Tsuzuki T; Yoshikawa K; Ueda R; Nagao T
Cancer Sci; 2021 Oct; 112(10):4037-4049. PubMed ID: 34309966
[TBL] [Abstract][Full Text] [Related]
3. Depletion of central memory CD8
Maeda Y; Wada H; Sugiyama D; Saito T; Irie T; Itahashi K; Minoura K; Suzuki S; Kojima T; Kakimi K; Nakajima J; Funakoshi T; Iida S; Oka M; Shimamura T; Doi T; Doki Y; Nakayama E; Ueda R; Nishikawa H
Nat Commun; 2021 Dec; 12(1):7280. PubMed ID: 34907192
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of anti-STLV-1/HTLV-1 immune responses through multimodal effects of anti-CCR4 antibody.
Sugata K; Yasunaga J; Miura M; Akari H; Utsunomiya A; Nosaka K; Watanabe Y; Suzushima H; Koh KR; Nakagawa M; Kohara M; Matsuoka M
Sci Rep; 2016 Jun; 6():27150. PubMed ID: 27250643
[TBL] [Abstract][Full Text] [Related]
5. Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive/refractory mycosis fungoides and Sézary syndrome.
Ni X; Jorgensen JL; Goswami M; Challagundla P; Decker WK; Kim YH; Duvic MA
Clin Cancer Res; 2015 Jan; 21(2):274-85. PubMed ID: 25376389
[TBL] [Abstract][Full Text] [Related]
6. Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas.
Remer M; Al-Shamkhani A; Glennie M; Johnson P
Immunotherapy; 2014; 6(11):1187-206. PubMed ID: 25496334
[TBL] [Abstract][Full Text] [Related]
7. Expansion of CD4+ cytotoxic T lymphocytes with specific gene expression patterns may contribute to suppression of tumor immunity in oral squamous cell carcinoma: single-cell analysis and
Chen H; Sameshima J; Yokomizo S; Sueyoshi T; Nagano H; Miyahara Y; Sakamoto T; Fujii S; Kiyoshima T; Guy T; Nakamura S; Moriyama M; Kaneko N; Kawano S
Front Immunol; 2023; 14():1305783. PubMed ID: 38077321
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma.
Watanabe Y; Katou F; Ohtani H; Nakayama T; Yoshie O; Hashimoto K
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 May; 109(5):744-52. PubMed ID: 20303300
[TBL] [Abstract][Full Text] [Related]
9. [Anti-CCR4 mAb and regulatory T cells].
Kurose K; Ohue Y; Oka M
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1150-5. PubMed ID: 24047773
[TBL] [Abstract][Full Text] [Related]
10. Blockade of CCR4 breaks immune tolerance in chronic hepatitis B patients by modulating regulatory pathways.
Khanam A; Ghosh A; Chua JV; Kottilil S
J Transl Med; 2023 Apr; 21(1):271. PubMed ID: 37081509
[TBL] [Abstract][Full Text] [Related]
11. Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study.
Zamarin D; Hamid O; Nayak-Kapoor A; Sahebjam S; Sznol M; Collaku A; Fox FE; Marshall MA; Hong DS
Clin Cancer Res; 2020 Sep; 26(17):4531-4541. PubMed ID: 32586937
[TBL] [Abstract][Full Text] [Related]
12. Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma.
Sun W; Li WJ; Wei FQ; Wong TS; Lei WB; Zhu XL; Li J; Wen WP
Oncotarget; 2016 Jun; 7(25):37714-37727. PubMed ID: 27177223
[TBL] [Abstract][Full Text] [Related]
13. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
[TBL] [Abstract][Full Text] [Related]
14. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.
Sugiyama D; Nishikawa H; Maeda Y; Nishioka M; Tanemura A; Katayama I; Ezoe S; Kanakura Y; Sato E; Fukumori Y; Karbach J; Jäger E; Sakaguchi S
Proc Natl Acad Sci U S A; 2013 Oct; 110(44):17945-50. PubMed ID: 24127572
[TBL] [Abstract][Full Text] [Related]
15. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy.
Yamauchi J; Coler-Reilly A; Sato T; Araya N; Yagishita N; Ando H; Kunitomo Y; Takahashi K; Tanaka Y; Shibagaki Y; Nishioka K; Nakajima T; Hasegawa Y; Utsunomiya A; Kimura K; Yamano Y
J Infect Dis; 2015 Jan; 211(2):238-48. PubMed ID: 25104771
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
Gao Y; You M; Fu J; Tian M; Zhong X; Du C; Hong Z; Zhu Z; Liu J; Markowitz GJ; Wang FS; Yang P
J Hepatol; 2022 Jan; 76(1):148-159. PubMed ID: 34689996
[TBL] [Abstract][Full Text] [Related]
17. Foxp3
Maeda S; Nakazawa M; Uchida M; Yoshitake R; Nakagawa T; Nishimura R; Miyamoto R; Bonkobara M; Yonezawa T; Momoi Y
Vet Pathol; 2020 Jul; 57(4):497-506. PubMed ID: 32347186
[TBL] [Abstract][Full Text] [Related]
18. A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.
Doi T; Muro K; Ishii H; Kato T; Tsushima T; Takenoyama M; Oizumi S; Gemmoto K; Suna H; Enokitani K; Kawakami T; Nishikawa H; Yamamoto N
Clin Cancer Res; 2019 Nov; 25(22):6614-6622. PubMed ID: 31455681
[TBL] [Abstract][Full Text] [Related]
19. Clinical Application of Anti-CCR4 Monoclonal Antibody.
Ueda R
Oncology; 2015; 89 Suppl 1():16-21. PubMed ID: 26550987
[TBL] [Abstract][Full Text] [Related]
20. Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma.
Watanabe K; Gomez AM; Kuramitsu S; Siurala M; Da T; Agarwal S; Song D; Scholler J; Rotolo A; Posey AD; Rook AH; Haun PL; Ruella M; Young RM; June CH
Blood Adv; 2023 Jul; 7(14):3416-3430. PubMed ID: 37058474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]